Aimmune Therapeutics Inc (NASDAQ:AIMT) to Release Earnings on Tuesday
Aimmune Therapeutics Inc (NASDAQ:AIMT) will post its quarterly earnings results after the market closes on Tuesday, August 8th. Analysts expect Aimmune Therapeutics to post earnings of ($0.64) per share for the quarter.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.05. On average, analysts expect Aimmune Therapeutics to post $-2.58 EPS for the current fiscal year and $-3.24 EPS for the next fiscal year.
Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) opened at 21.52 on Monday. Aimmune Therapeutics Inc has a one year low of $12.05 and a one year high of $27.31. The company’s 50 day moving average price is $20.56 and its 200 day moving average price is $19.90. The firm’s market capitalization is $1.08 billion.
TRADEMARK VIOLATION WARNING: “Aimmune Therapeutics Inc (NASDAQ:AIMT) to Release Earnings on Tuesday” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/07/aimmune-therapeutics-inc-nasdaqaimt-to-release-earnings-on-tuesday.html.
In other news, insider Stephen George Dilly sold 49,400 shares of the company’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $20.21, for a total transaction of $998,374.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Eric Bjerkholt bought 5,000 shares of Aimmune Therapeutics stock in a transaction dated Friday, May 12th. The shares were bought at an average cost of $19.84 per share, with a total value of $99,200.00. Following the completion of the acquisition, the chief financial officer now owns 5,000 shares of the company’s stock, valued at $99,200. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 189,070 shares of company stock valued at $3,954,182. 24.56% of the stock is currently owned by company insiders.
Several research analysts have recently issued reports on AIMT shares. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Tuesday, May 16th. ValuEngine upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Finally, Wedbush restated an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $33.00.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.